Stipe Therapeutics logo

Stipe Therapeutics jobs and careers

About Stipe Therapeutics

STipe Therapeutics focuses on harnessing the innate immune system to battle cancer. The company has developed first-in-class drugs targeting intracellular protein-protein interactions of the STING Pathway; a major driver of innate immunity, and regulator of tumorigenesis and autoimmune disorders. The company has identified and validated compoundsthat sensitizes the STING pathway and by this modulates the tumor microenvironment to support a potent anti-tumoral response.

Founded in 2018 by Claus Elsborg Olesen and Martin Roelsgaard Jakobsen.

Founded
2018
Employees
11 to 50
Total funding
$20M

Leadership

The top of Stipe Therapeutics's org chart, with how many people report into each leader.

COPhoto of Claus Olesen

Claus Olesen

Co-Founder/CEO

1 report

JJPhoto of Justin Joseph

Justin Joseph

Senior Scientist